Skip to main content

A novel genetic assay for risk assessment of cognitive decline in Alzheimer’s Disease

Project description

Earlier diagnosis of Alzheimer's by a new genetic assay

Early diagnosis of Alzheimer’s disease relies on testing that is not easily applicable to the broader population. However, early diagnosis for both families and health providers are crucial as its incidence is expected to triple by 2050 from the current estimate of 45 million. The variaTECT method uses 130K single nucleotide polymorphism (SNP) testing and software to analyse DNA extracts from blood or saliva samples. It is 85 % accurate with significant cost savings for patients and revenue for genetic laboratories. The project will upgrade variaTECT’s design to determine dementia types and increase production capacity, aiming for clinical trials for an in-vitro diagnostic device.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
53 Fountain Street
M2 2AN Manchester
United Kingdom

See on map

North West (England) Greater Manchester Manchester
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00